Limitations of direct estradiol and testosterone immunoassay kits

被引:144
作者
Stanczyk, FZ
Cho, MM
Endres, DB
Morrison, JL
Patel, S
Paulson, RJ
机构
[1] Womens & Childrens Hosp, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA
[2] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA
[3] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
关键词
estradiol (E-2); testosterone (T); RIA;
D O I
10.1016/j.steroids.2003.08.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Estradiol (E-2) and testosterone (T) are biologically active hormones that serve as important diagnostic markers in serum of premenopausal and postmenopausal women and in men. These hormones are measured frequently by immunoassay in clinical laboratories and the test results are used in the diagnosis and treatment of patients. For measuring the hormones by immunoassay, most laboratories utilize commercially available reagents that are packaged in the form of a kit and are used either in an automated instrument or manually. However, both the diagnostic kit manufacturer and testing laboratory seldom thoroughly validate the assay methods generated with these kits. This deficiency may lead to unreliable test results that could affect clinical evaluation and treatment of patients. The purpose of the present study was to assess the reliability of immunoassays that quantify serum E-2 and T levels with commercial diagnostic kits. The data generally show wide differences in the apparent levels of each hormone in a given sample obtained with kits from different manufacturers. This was especially true when measuring postmenopausal E-2 and T levels. However, a purification step, which included organic solvent extraction, prior to radioimmunoassay (RIA) of E-2 gave values that compared well with those obtained by conventional RIA (with preceding extraction/chromatographic steps). Our results point out the importance of more thoroughly validating assays performed with commercial immunoassay kits, especially with respect to sensitivity and specificity, prior to their use for measuring hormone levels in patient samples. (C) 2003 Published by Elsevier Inc.
引用
收藏
页码:1173 / 1178
页数:6
相关论文
共 21 条
[1]  
BARNES RB, 1999, TREATMENT POSTMENOPA, P95
[2]   Measurement of total serum testosterone levels using commercially available kits: High degree of between-kit variability [J].
Boots, LR ;
Potter, S ;
Potter, HD ;
Azziz, R .
FERTILITY AND STERILITY, 1998, 69 (02) :286-292
[3]  
COOK NJ, 1995, BRIT J BIOMED SCI, V52, P97
[4]   MONITORING OF HORMONE REPLACEMENT THERAPY [J].
DIVER, MJ .
LANCET, 1992, 340 (8833) :1471-1471
[5]  
Fitzgerald RL, 1996, CLIN CHEM, V42, P749
[6]   SERUM TESTOSTERONE CONCENTRATIONS IN WOMEN THROUGHOUT MENSTRUAL-CYCLE AND FOLLOWING HCG ADMINISTRATION [J].
GOEBELSMANN, U ;
ARCE, JJ ;
THORNEYCROFT, IH ;
MISHELL, DR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1974, 119 (04) :445-452
[7]  
Goebelsmann U.B.G., 1979, VASECTOMY IMMUNOLOGI, P165
[8]  
LEE CS, 1991, J REPROD MED, V36, P156
[9]  
NAKAMURA RM, 1997, MISHELLS TXB INFERTI, P76
[10]  
NISBET JA, 1987, CLIN CHEM, V33, P1672